We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$489M
AUM Growth
+$31.8M
Cap. Flow
+$66.3M
Cap. Flow %
13.55%
Top 10 Hldgs %
49.33%
Holding
85
New
24
Increased
27
Reduced
16
Closed
16

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$12.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$9.19M
4
SLNO
Soleno Therapeutics
SLNO
+$8.1M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.71M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$17.3M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15M
3
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$9.72M
4
SRRK icon
Scholar Rock
SRRK
+$7.92M
5
COGT icon
Cogent Biosciences
COGT
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
26
Praxis Precision Medicines
PRAX
$8.58B
$6.29M 1.29%
166,074
+93,558
+129% +$5.84M
MLYS icon
27
Mineralys Therapeutics
MLYS
$2.31B
$5.37M 1.1%
+338,354
New +$3.89M
CGEN icon
28
Compugen
CGEN
$221M
$4.23M 0.86%
2,895,430
+1,271,053
+78% +$2.48M
TARS icon
29
Tarsus Pharmaceuticals
TARS
$2.6B
$4.18M 0.85%
81,331
+15,376
+23% +$760K
ALKS icon
30
Alkermes
ALKS
$8.39B
$4.12M 0.84%
+124,871
New +$4.07M
OCUL icon
31
Ocular Therapeutix
OCUL
$1.85B
$4.04M 0.83%
+551,570
New +$4.24M
BBIO icon
32
BridgeBio Pharma
BBIO
$16.1B
$3.84M 0.78%
+111,000
New +$3.74M
KURA icon
33
Kura Oncology
KURA
$826M
$3.84M 0.78%
+581,369
New +$4.53M
CLDX icon
34
Celldex Therapeutics
CLDX
$3.02B
$3.74M 0.76%
205,962
-58,598
-22% -$1.31M
DNTH icon
35
Dianthus Therapeutics
DNTH
$6.16B
$3.45M 0.71%
+190,334
New +$4.19M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$11.4B
$3.43M 0.7%
+10,344
New +$3.4M
CERS icon
37
Cerus
CERS
$579M
$3.41M 0.7%
2,456,537
+869,309
+55% +$1.45M
TELA icon
38
TELA Bio
TELA
$31.8M
$3.38M 0.69%
2,771,288
-294,361
-10% -$724K
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$3.35M 0.68%
232,758
-366,194
-61% -$5.99M
TRVI icon
40
Trevi Therapeutics
TRVI
$2.61B
$3.33M 0.68%
530,000
-204,234
-28% -$974K
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$3.31M 0.68%
+37,345
New +$3.64M
GPCR icon
42
Structure Therapeutics
GPCR
$3.52B
$3.26M 0.67%
188,069
+35,674
+23% +$874K
BNTC icon
43
Benitec Biopharma
BNTC
$407M
$3.25M 0.67%
+250,000
New +$3.02M
LQDA icon
44
Liquidia Corp
LQDA
$7.72B
$3.16M 0.65%
+214,057
New +$3.12M
PTCT icon
45
PTC Therapeutics
PTCT
$6.26B
$3.08M 0.63%
+60,389
New +$3.01M
MTSR
46
DELISTED
Metsera Inc
MTSR
$3.07M 0.63%
+112,759
New +$3.2M
SLNO
47
PUT
DELISTED
Soleno Therapeutics
SLNO
$3.04M 0.62%
+42,500
New +$2.07M
BDSX icon
48
Biodesix
BDSX
$221M
$2.56M 0.52%
204,920
-11,694
-5% -$224K
DCTH icon
49
Delcath Systems
DCTH
$416M
$2.44M 0.5%
191,470
+36,145
+23% +$513K
QURE icon
50
uniQure
QURE
$2.93B
$2.16M 0.44%
203,400
+103,400
+103% +$1.45M
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Silverarc Capital Management held 85 positions worth $489M, up 7% from $457M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Silverarc Capital Management deployed $66.3M of net new capital in Q1 2025, opening 24 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 72,583 shares worth $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Centessa Pharmaceuticals, an estimated $5.99M trimmed.

  • Silverarc Capital Management's largest Q1 2025 buy was Neurocrine Biosciences: 72,583 shares worth $8.03M.
  • Silverarc Capital Management added most to 89bio in Q1 2025, an estimated $12.4M increase.
  • Silverarc Capital Management's biggest Q1 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $5.99M.
  • Silverarc Capital Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $17.3M.
  • Silverarc Capital Management's ten largest holdings make up 49% of its $489M portfolio in Q1 2025.
  • Silverarc Capital Management opened 24 new positions and closed 16 in Q1 2025.
  • Silverarc Capital Management's portfolio value rose 7% quarter-over-quarter to $489M.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.